AffiAB® Anti-HLA-DP Antibody [PD00-70]

https://www.affiab.com/web/image/product.template/100537/image_1920?unique=b83e256
(0 review)

CAT# AFG-HB-1889
Size: 100 μL

496.50 496.5 USD 496.50

496.50

For Price Contact info@affigen.com

This combination does not exist.

Terms and Conditions
30-day money-back guarantee
Shipping: 2-3 Business Days

AffiAB® Anti-HLA-DP Antibody [PD00-70]

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide) . The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

Antibody type

Recombinant Rabbit monoclonal Antibody

Uniprot ID

SwissProt: P20036 Human

Recombinant

YES

Conjugation

Non-conjugated

Host

Rabbit

Isotype

IgG

Clone

PD00-70

KO/KD

N/A

Species reactivity

Human

Tested applications

IHC-P, FC

Predicted species reactivity

N/A

Immunogen

Synthetic peptide.

Storage

Store at +4°C after thawing. Aliquot store at -20°C. Avoid repeated freeze / thaw cycles.

Form

Liquid

Storage buffer

PBS (pH7.4) , 0.1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

1 mg/mL.

Purity

Protein A affinity purified.

Signal pathway

N/A

Recommended dilutions

IHC-P: 1:200-1:500 ; FC: 1:500-1:1, 000

Molecular Weight

Predicted band size: 29 kDa

Subcellular location

Cell membrane, Endoplasmic reticulum membrane, Golgi apparatus, Endosome membrane, Lysosome membrane.

Positive control

Human tonsil tissue, human diffuse large B-cell lymphoma tissue, Daudi.